Ilsung Pharmaceuticals

What Ilsung Pharmaceuticals does

Ilsung Pharmaceuticals (Ilsung IS Co., Ltd., 일성아이에스 주식회사) is a South Korea-based pharmaceutical manufacturer with approximately seventy years of operating history, headquartered in Gwacheon, Gyeonggi-do, and listed on the Korea Exchange under ticker 003120 (previously operating as Ilsung Sinjak / 일성신약 before a 2024 corporate rebrand). The company manufactures and distributes a horizontally diversified portfolio of prescription pharmaceuticals across six therapeutic categories — cardiovascular (e.g., Pietazt, Telmitrizone, Double Star), gastrointestinal (Caraduo, Lansomel), antiemetic (Ramonoxi Injection), anticoagulant (Rimapros), respiratory (Acebrophyll, Pimasav, Azelblock, Sarpog SR, Penolate), and analgesics (loxoprofen and zaltoprofen tablets) — as well as a small medical-device line (GuardianWrap and GuardianWrap Plus wound-care products). Production runs across two company-owned facilities, the main factory and the Ansan factory, both covered by integrated ISO 14001 and ISO 45001 certifications, with manufacturing capabilities spanning tablet, capsule, and injectable dosage forms.

The company's revenue model is a domestic Korean prescription-pharma distribution business selling to healthcare institutions (hospitals, clinics, pharmacies) through a B2B web ordering portal (order.ilsung-ph.co.kr) plus direct field distribution and a network of sales branches. Pricing is not publicly disclosed and channels are prescription- and institution-mediated. Ilsung IS maintains a full investor-relations section (financial information, public disclosures, electronic public notices, annual business reports) consistent with its KRX listing, and pursues an operational positioning around "Innovative Science" and future biotechnology-industry leadership, while remaining a domestic single-geography operator with no disclosed international expansion. Recent material actions include a national Order of Industrial Merit award at the 39th Pharmacy Day, integrated environmental/safety certification, the GuardianWrap Plus product launch, and several voluntary product recalls disclosed through the company website.

Name

Ilsung Pharmaceuticals

Legal name

Ilsung IS Co., Ltd. (일성아이에스(주))

Website

https://ilsung-ph.co.kr

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

101–250 employees

Short description

Ilsung Pharmaceuticals (Ilsung IS) is a South Korean generic-drug manufacturer with ~70 years of history, producing prescription medications across cardiovascular, gastrointestinal, respiratory, and pain categories plus medical devices, distributed to Korean hospitals and pharmacies.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Generic pharmaceuticals
• Prescription medications
• Cardiovascular therapeutics
• Wound care devices
• Gastrointestinal medications

Headquarters

HQ city

Yongsan

HQ country

South Korea

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels2 records

Marketing channels3 records

Core offering

Ilsung Pharmaceuticals manufactures and distributes a diversified portfolio of generic prescription pharmaceuticals across cardiovascular, gastrointestinal, anti-nausea, anticoagulant, antidiabetic, antibiotic, hepatobiliary, and analgesic categories, plus wound-care medical devices (film-former dressings and medicated gauze). Products are sold primarily to Korean healthcare institutions via direct sales and a web-based ordering platform.

Product overview

Ilsung Pharmaceuticals (Ilsung IS Co., Ltd.) operates as a pharmaceutical company offering a diversified portfolio of generic and branded medications across multiple therapeutic areas. The product portfolio includes: (1) Cardiovascular medications such as Pietazt Tablet and Telmitrizone Tablet; (2) Gastrointestinal medications including Caraduo Tablet and Lansomel Capsule (lansoprazole formulation); (3) Anti-nausea medication Ramonoxi Injection; (4) Anticoagulant Rimapros Tablet; (5) Medical devices GuardianWrap and GuardianWrap Plus; (6) Analgesics including Ilsung Loxoprofen Sodium Hydrate Tablet and Ilsung ZalToprofen Tablet; and (7) Respiratory treatments including Acebrophyll Capsule, Pimasav Tablet, Azelblock Tablet, Sarpog SR Tablet, Penolate Tablet, and Double Star Tablet in various combinations and dosages. The company also markets popular products such as Augmentin (오구멘틴), Won Alpha (원알파), Rayfam (레이팜), Sebofrein (세보프레인), and Hoifan (호이판) as reflected in search trends.

Differentiator

Problem solved

Functional benefit

Brands

• 가디언랩 (GuardianWrap): Medical device product line including GuardianWrap and GuardianWrap Plus.

Products and services

• Pietazt Tablet

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• ENAGE Inc.minorOthersENAGE Inc. (www.enage.com) provides the groupware system (그룹웨어) for Ilsung IS's internal communications and workflow management. The groupware portal at gw.ilsung-ph.co.kr is powered by ENAGE technology, indicating an IT infrastructure partnership for enterprise software operations.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Yuhan Corporation: Korean pharma manufacturer with broad prescription and OTC portfolio across multiple therapeutic classes including GI and respiratory. Comparable in product breadth and Korean distribution model, though Yuhan is significantly larger.
• Bukwang Pharmaceutical: Korean pharmaceutical company with branded generic and specialty drug portfolio across multiple therapeutic categories. Comparable as a domestic finished-dose manufacturer with hospital and pharmacy channel sales.
• Jeil Pharmaceutical: Korean mid-cap pharmaceutical manufacturer with a portfolio of prescription generics in cardiovascular, GI, and respiratory categories. Comparable in size, product mix, and domestic-focused distribution.
• Samjin Pharmaceutical: Korean mid-cap pharmaceutical manufacturer with a portfolio of prescription generics in cardiovascular, GI, and respiratory areas. Comparable in scale, product mix, and Korean domestic distribution model.
• Dong-A Pharmaceutical: Long-established Korean pharmaceutical manufacturer with a broad generics and OTC portfolio including cardiovascular, GI, and respiratory products. Highly comparable legacy business model and domestic distribution focus.
• Daewoong Pharmaceutical: One of Korea's largest domestic pharma manufacturers with a broad generics and specialty portfolio across GI, cardiovascular, and respiratory categories. Directly comparable to Ilsung IS in therapeutic area coverage and Korean-market focus, though Daewoong is materially larger and more R&D-intensive.
• Chong Kun Dang Pharmaceutical: Korean pharma manufacturer with branded generics across cardiovascular, GI, and central nervous system categories. Comparable as a domestic mid-cap finished-dose producer selling through Korean hospital and pharmacy channels.
• Hanmi Pharmaceutical: Korean pharma company with a diversified finished-dose and specialty drug portfolio targeting cardiovascular, GI, and respiratory indications. Comparable to Ilsung IS in product breadth and channel mix, with a stronger export footprint.

Broad incumbents

• SK Bioscience: Korean vaccine and biopharmaceutical manufacturer with prescription drug operations. Comparable as a listed Korean pharma manufacturer, though its portfolio centers on vaccines and biologics rather than Ilsung IS's small-molecule generic focus.
• LG Chem (Life Sciences): Diversified Korean chemical and life sciences conglomerate with a sizable pharmaceutical business spanning branded generics, specialty drugs, and biologics. Comparable in finished-dose manufacturing and Korean distribution, though much larger and more diversified.

Market position

Strengths6 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ilsung Pharmaceuticals